Please do not leave this page until complete. This can take a few moments.
GeneDx, a Stamford-based genomic testing firm formerly known as Sema4, has agreed to acquire California-based genomics software company Fabric Genomics for up to $51 million.
Rallybio, a New Haven-based biotechnology firm, said Tuesday it has discontinued development of a therapy intended to prevent a rare immune disorder in fetuses and newborns.
Five months after being granted a reprieve from b
Pass-through business entities with research and development expenses would receive a tax credit under a bill being considered by state lawmakers.
BioXcel Therapeutics Inc., a New Haven-based biopharmaceutical company, said it has raised $14 million from a registered direct offering.
Just three weeks after executing a 1-for-16 reverse stock split of its common stock, New Haven-based biopharmaceutical company BioXcel Therapeutics Inc. on Friday announced it has avoided being delisted from the Nasdaq stock market.
Rallybio, a New Haven-based biotechnology firm, notified federal regulators this week that it faces delisting from the Nasdaq Stock Market.
The state’s bioscience sector is a lot like that box of chocolates in the film “Forrest Gump” — you never know what you’re going to get. Several state-based companies have recently suffered significant financial woes:
When Gov. Ned Lamont addressed BioCT’s 2025 legislative breakfast on Jan. 27 in New Haven, his keynote address included a surprise.
Stamford-based SpringWorks Therapeutics, a commercial-stage biotech company developing treatments for rare diseases and cancer, is in “advanced talks” to be acquired by Germany’s Merck, according to Reuters.
Connecticut and 21 other states jointly sued the federal government on Monday over the administration’s move to slash funding provided to research institutions through the National Institutes of Health.
Biotechnology firm Hyperfine Inc., an emerging growth company based in Guilford, announced Wednesday that it is cutting about 14% of its global workforce amid widening losses.
Two bills proposed in the 2025 legislative session seek to create or expand economic development zones in the town of Plainville.
A Westport-based startup that applies artificial intelligence to biomedical research has received a $4 million investment.
State health regulators said Friday they have reached an agreement that will allow for the development of a second proton beam therapy center in Connecticut.
Azitra Inc., a Branford-based biopharmaceutical firm, has announced the pricing for a public offering of its common stock.